Furthermore, in the field of MVA-based HIV/AIDS vaccine candidates, a previous report has already correlated a 4- to 7-fold enhanced expression of HIV-1 Env antigen driven by the strong mH5 promoter with a significant increase in Env-specific CD4+ (1 to 2-fold) and CD8+ T (3- to 5-fold) cell responses [19]. This evidence concerns the gene ERVW-1 and AIDS.